tiprankstipranks
Avenue Therapeutics reports Q1 EPS ($15.40) vs ($101.57) last year
PremiumThe FlyAvenue Therapeutics reports Q1 EPS ($15.40) vs ($101.57) last year
2M ago
Avenue Therapeutics files to sell 1.42M shares of common stock for holders
PremiumThe Fly
Avenue Therapeutics files to sell 1.42M shares of common stock for holders
2M ago
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
PremiumPress Releases
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
3M ago
Avenue Therapeutics announces 1-for-75 reverse stock split
PremiumThe FlyAvenue Therapeutics announces 1-for-75 reverse stock split
3M ago
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
PremiumPress Releases
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
4M ago
Navigating the Maze: Avenue Therapeutics Grapples with Regulatory Hurdles for IV Tramadol
PremiumCompany Announcements
Navigating the Maze: Avenue Therapeutics Grapples with Regulatory Hurdles for IV Tramadol
4M ago
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
PremiumPress ReleasesAvenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
4M ago
ATXI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
ATXI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
5M ago
Avenue Therapeutics Shareholders Approve Stock Capacity Hike
PremiumCompany Announcements
Avenue Therapeutics Shareholders Approve Stock Capacity Hike
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100